HOPKINTON, Mass. and TOKYO, Aug. 9, 2024 ~ Phosphorex, a leading contract development and manufacturing organization (CDMO) focused on drug delivery, has announced a strategic investment from NOF CORPORATION. This investment marks a significant milestone in Phosphorex's growth and development journey, as the company continues to expand its capabilities and strengthen its collaboration with NOF.

According to Jarlath Keating, CEO of Phosphorex, this partnership will play a crucial role in advancing the company's growth plans and enhancing the value it provides to clients and stakeholders. The investment from NOF CORPORATION will be used to accelerate the establishment of Phosphorex's cGMP capability, further solidifying its position as a global leader in nanoparticle-based drug delivery.

More on Boston Chron

• Lottery.com Inc. Secures $300 Million in Growth Capital, Confirms Nasdaq Compliance & Acquires UAE Sports Incubator Amid High-Profile Brand Exposure
• $750 Million Ketamine Drug Market Withing Reach via New Commissioner's National Priority Vouchers with Anticipated Approval by Year-End for NRx
• NUFABRX awarded Therapeutic Compression agreement with Premier, Inc
• Luxurious Estate in Keenes Pointe Hits the Market at $2.9 Million
• CredHub and ManageAmerica Partner to Empower Residents Through Seamless Rent Reporting Integration

The addition of NOF CORPORATION as a minority shareholder is a testament to their confidence in Phosphorex's innovative approach to drug delivery. As Keating explains, "Their support and expertise will be invaluable as we continue our vision of enabling the development of novel therapeutics to improve the lives of patients."

Yuji Yamamoto, General Manager of Life Science division at NOF CORPORATION, also expressed excitement about this partnership. He believes that it will bring numerous benefits to Phosphorex, including increased funding, strategic support, and other advantages. The collaboration between the two companies will further enable Phosphorex's mission to become the leading CDMO for nanoparticle-based drug delivery solutions.

Additionally, this investment will also help consolidate NOF's position in the lipid nanoparticle (LNP)-based drug delivery market through its COATSOME® SS Series of proprietary ionizable lipids. With this partnership, both companies are poised for continued success in the rapidly growing field of drug delivery.

---

Show All News | Report Violation